Figure 5.

IFN-β therapy renders T cells responsiveness against suppressive function of Treg in vivo. (A) Shown are mice 20 days after transfer of PBMC from HD or IFN-β-treated MS patients with injection of gp120 compared with untreated mice; (B) Treg were depleted within PBMC of HD (black) or IFN-β-treated MS patients (blue) and replaced with the same amount of Treg from an independent HD. Subsequently, 5 × 10⁶ cells were injected with or without gp120 (5 g/mouse) intraperitoneally into newborn NOD/Scidγc^−/− mice. Untreated mice served as controls (n = 5). Each point represents the cumulative mean weight of one group (five mice per group), p-values relative to mean body weight of mice administered with PBMC from IFN-β-treated MS patients with Treg * p < 0.05, ** p < 0.01 are shown. n.s. means no significance. (Right) survival of mice in Kaplan–Meier plot within 30 days is shown. One of four independent experiments is shown.